Protagonist Therapeutics is at the forefront of developing peptide therapeutics across key areas, including inflammatory diseases, obesity, and iron regulation.
The subcutaneous hepcidin mimetic rusfertide offers a novel approach to managing chronic stress erythropoiesis. By mimicking the natural function of hepcidin, rusfertide regulates iron homeostasis through enhanced iron sequestration, providing a targeted therapeutic option for conditions such as polycythemia vera. This mechanism represents a compelling alternative to traditional treatments, which often have significant limitations.
This presentation will highlight Protagonist’s innovative strategies in developing next-generation peptide therapeutics, with a particular focus on iron regulation. These advancements have the potential to transform the treatment landscape and address critical unmet medical needs.